Silvestris N - Search Results

1

Rapid Serological Assays and SARS-CoV-2 Real-Time Polymerase Chain Reaction Assays for the Detection of SARS-CoV-2: Comparative Study.

Paradiso AV, De Summa S, Loconsole D, Procacci V, Sallustio A, Centrone F, Silvestris N, Cafagna V, De Palma G, Tufaro A, Garrisi VM, Chironna M. Paradiso AV, et al. Among authors: silvestris n. J Med Internet Res. 2020 Oct 30;22(10):e19152. doi: 10.2196/19152. J Med Internet Res. 2020. PMID: 33031048 Free PMC article.

2

mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer.

Paradiso A, Ranieri G, Simone G, Silvestris N, Costa A, De Lena M, Leone A, Vallejo C, Lacava J. Paradiso A, et al. Among authors: silvestris n. Oncology. 2002;62(3):278-85. doi: 10.1159/000059576. Oncology. 2002. PMID: 12065876

3

p53 as the main traffic controller of the cell signaling network.

Sebastian S, Azzariti A, Silvestris N, Porcelli L, Russo A, Paradiso A. Sebastian S, et al. Among authors: silvestris n. Front Biosci (Landmark Ed). 2010 Jun 1;15(3):1172-90. doi: 10.2741/3669. Front Biosci (Landmark Ed). 2010. PMID: 20515749 Free article. Review.

4

The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy.

Azzariti A, Porcelli L, Quatrale AE, Silvestris N, Paradiso A. Azzariti A, et al. Among authors: silvestris n. Curr Drug Metab. 2011 Oct;12(8):713-21. doi: 10.2174/138920011798357042. Curr Drug Metab. 2011. PMID: 21434858 Review.

5

Oncosuppressor methylation: a possible key role in colon metastatic progression.

Tommasi S, Pinto R, Petriella D, Pilato B, Lacalamita R, Santini D, Zito F, Colucci G, Paradiso A, Silvestris N. Tommasi S, et al. Among authors: silvestris n. J Cell Physiol. 2011 Jul;226(7):1934-9. doi: 10.1002/jcp.22524. J Cell Physiol. 2011. PMID: 21506124

6

Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients.

Gnoni A, Russo A, Silvestris N, Maiello E, Vacca A, Marech I, Numico G, Paradiso A, Lorusso V, Azzariti A. Gnoni A, et al. Among authors: silvestris n. Curr Drug Metab. 2011 Dec;12(10):918-31. doi: 10.2174/138920011798062300. Curr Drug Metab. 2011. PMID: 21787270 Review.

7

Overexpression of nuclear NHERF1 in advanced colorectal cancer: association with hypoxic microenvironment and tumor invasive phenotype.

Malfettone A, Silvestris N, Paradiso A, Mattioli E, Simone G, Mangia A. Malfettone A, et al. Among authors: silvestris n. Exp Mol Pathol. 2012 Jun;92(3):296-303. doi: 10.1016/j.yexmp.2012.03.004. Epub 2012 Mar 13. Exp Mol Pathol. 2012. PMID: 22440733

8

Synthetic lethality to overcome cancer drug resistance.

Porcelli L, Quatrale AE, Mantuano P, Silvestris N, Brunetti AE, Calvert H, Paradiso A, Azzariti A. Porcelli L, et al. Among authors: silvestris n. Curr Med Chem. 2012;19(23):3858-73. doi: 10.2174/092986712802002563. Curr Med Chem. 2012. PMID: 22788762 Review.

9

Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors.

Porcelli L, Quatrale AE, Mantuano P, Silvestris N, Rolland JF, Biancolillo L, Paradiso A, Azzariti A. Porcelli L, et al. Among authors: silvestris n. Curr Pharm Des. 2013;19(5):918-26. Curr Pharm Des. 2013. PMID: 22973960 Review.

10

Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.

Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A, Azzariti A. Porcelli L, et al. Among authors: silvestris n. Mol Oncol. 2013 Jun;7(3):308-22. doi: 10.1016/j.molonc.2012.10.002. Epub 2012 Oct 29. Mol Oncol. 2013. PMID: 23148997 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

390 results

Search Page

Filters